Clareo Health | A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
ECOG performance status of 0 or 1
Advanced, histologically documented epithelial ovarian, primary peritoneal, or fallopian tube cancer that has progressed or relapsed during or within 12 months of treatment with a platinum-containing chemotherapy regimen, and for which no standard therapy exists
History of receiving five or fewer prior chemotherapy-containing regimens for EOC, PPC, or FTC (including primary therapy)
You may not be if
Prior treatment with chemotherapy or experimental anti-cancer agents within 4 weeks prior to Day 1
Prior treatment with oregovomab (OvaRex(R)) or abagovomab
History or clinical evidence of central nervous system or brain metastases
Grade ≥ 2 peripheral neuropathy
History of severe allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies
History of clinically symptomatic liver disease, including viral or other hepatitis, history of or current alcoholism, or cirrhosis
Untreated or persistent/recurrent malignancy (other than EOC, PPC, or FTC)
